Home Haematology and Oncology Page 3

Category: Haematology and Oncology

Drugs in Context Haematology welcomes a broad range of article types including original research, study protocols and review articles.

In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

Jonathan Wadsley, Alan Christie, Roopinder Gillmore, Amy Trinh, Rachel Greig

Article Type

Case Series

Published

14 Aug 2023

Three clinical cases are presented in this article to illustrate the position of pemigatinib in the management of cholangiocarcinoma and related toxicities.

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology

Article Type

Original Research

Published

21 Jun 2023

In this study, the authors investigated the toxicity and efficacy of cabozantinib in Chinese patients who progressed on VEGFR TKIs and/or ICIs in real-life clinical practice.

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy

Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti

Article Type

Original Research

Published

20 Jun 2023

This real-life study investigated the link between clinical complexity and quality of life of patients with HR+/HER2– advanced breast cancer treated with CDK4/6 inhibitors.

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

Andrea De Giglio, Biagio Ricciuti, Giulio Metro

Article Type

Editorial

Published

02 May 2023

This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all.

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti

Article Type

Review

Published

02 May 2023

This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies.